Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a clinical study titled ‘Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)’. The study aims to assess the efficacy and safety of dupilumab over a 24-week treatment period in adults suffering from chronic pruritus of unknown origin, a condition characterized by severe itching without a known cause.
The intervention being tested is dupilumab, an injectable drug administered subcutaneously every two weeks. It is intended to alleviate severe itching in conjunction with a non-sedative antihistamine and a moisturizer.
This Phase 3 study is designed as a randomized, double-blind, placebo-controlled, parallel-group trial. Participants are randomly assigned to receive either dupilumab or a placebo, with both the participants and the study personnel blinded to the assignments. The primary purpose is to evaluate the treatment’s effectiveness.
The study began on February 22, 2022, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and potential market entry of the treatment.
Sanofi’s ongoing study could significantly impact its stock performance, as successful results may lead to a new treatment option for chronic pruritus, potentially increasing market share. Investors should monitor this study’s progress, especially in the context of competing treatments in the dermatology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.